HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francesco Panza Selected Research

solanezumab

1/2018The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
10/2014Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
9/2014Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
3/2014Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
2/2012Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francesco Panza Research Topics

Disease

94Alzheimer Disease (Alzheimer's Disease)
08/2022 - 09/2002
60Cognitive Dysfunction
08/2022 - 04/2005
51Dementia (Dementias)
11/2021 - 04/2005
16Stroke (Strokes)
01/2021 - 04/2006
15Frailty
03/2022 - 04/2012
10Amyloid Plaque
08/2022 - 02/2006
8Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
01/2019 - 09/2002
7Hypertension (High Blood Pressure)
02/2022 - 04/2006
7Pain (Aches)
01/2019 - 07/2009
5Overweight
01/2022 - 10/2020
5Language Development Disorders (Semantic-Pragmatic Disorder)
01/2021 - 01/2019
5Frontotemporal Dementia (Semantic Dementia)
01/2019 - 08/2006
5Muscle Spasticity (Spastic)
07/2017 - 10/2010
5Coronary Artery Disease (Coronary Atherosclerosis)
12/2016 - 04/2002
5Vascular Diseases (Vascular Disease)
12/2009 - 03/2003
4Depressive Disorder (Melancholia)
01/2021 - 01/2017
4Inflammation (Inflammations)
01/2020 - 02/2006
4Neurobehavioral Manifestations
01/2020 - 08/2009
4Mental Disorders (Mental Disorder)
01/2019 - 12/2016
4Drug-Related Side Effects and Adverse Reactions
09/2018 - 09/2011
4Disease Progression
12/2017 - 03/2011
4Major Depressive Disorder (Major Depressive Disorders)
01/2017 - 10/2012
4Malnutrition (Nutritional Deficiencies)
01/2016 - 11/2006
4Parkinson Disease (Parkinson's Disease)
01/2016 - 04/2008
4Meningoencephalitis
03/2014 - 11/2010
4Edema (Dropsy)
02/2012 - 11/2010
4Cerebrovascular Disorders (Cerebrovascular Occlusion)
12/2007 - 04/2006
3Type 2 Diabetes Mellitus (MODY)
12/2021 - 04/2002
3Obesity
12/2021 - 10/2020
3Hearing Loss (Hearing Impairment)
11/2021 - 01/2019
3Neoplasms (Cancer)
11/2021 - 01/2007
3Hallucinations (Hallucination)
02/2021 - 04/2011
3Diabetes Mellitus
01/2021 - 01/2015
3Chronic Disease (Chronic Diseases)
10/2020 - 04/2005
3Movement Disorders (Movement Disorder)
09/2017 - 01/2010
3Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017 - 10/2010
3Pressure Ulcer (Bedsore)
01/2016 - 01/2012
3Atherosclerosis
04/2010 - 04/2006
2Fatty Liver
01/2022 - 04/2021
2Non-alcoholic Fatty Liver Disease
12/2021 - 04/2021
2Sarcopenia
12/2021 - 12/2017
2Liver Cirrhosis (Hepatic Cirrhosis)
11/2021 - 01/2020
2Periodontal Diseases (Periodontal Disease)
11/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

31Amyloid (Amyloid Fibrils)IBA
08/2022 - 04/2004
26ApolipoproteinsIBA
01/2022 - 03/2003
21Apolipoproteins E (ApoE)IBA
01/2022 - 03/2003
19Type A Botulinum Toxins (Botox)FDA Link
02/2019 - 04/2008
19Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
12/2018 - 04/2005
17Proteins (Proteins, Gene)FDA Link
09/2020 - 04/2004
15Biomarkers (Surrogate Marker)IBA
01/2022 - 02/2006
13Peptides (Polypeptides)IBA
01/2020 - 01/2009
12Biological ProductsIBA
01/2022 - 03/2004
12Fatty Acids (Saturated Fatty Acids)IBA
12/2018 - 04/2005
11CholesterolIBA
01/2021 - 02/2006
10AntioxidantsIBA
12/2018 - 03/2006
10Monounsaturated Fatty AcidsIBA
01/2017 - 04/2005
9Pharmaceutical PreparationsIBA
08/2022 - 06/2011
7tau Proteins (tau Protein)IBA
01/2020 - 12/2009
7Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2017 - 05/2009
7bapineuzumabIBA
10/2014 - 11/2010
7Amyloid beta-PeptidesIBA
02/2010 - 09/2002
6LipidsIBA
09/2019 - 04/2006
6incobotulinumtoxinAFDA Link
02/2019 - 03/2013
6VaccinesIBA
01/2017 - 11/2010
6Monoclonal AntibodiesIBA
01/2016 - 11/2010
6Lipoproteins (Lipoprotein)IBA
12/2009 - 04/2002
5Cytochrome P-450 CYP2D6 (CYP2D6)IBA
09/2018 - 10/2015
5solanezumabIBA
01/2018 - 02/2012
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2016 - 04/2006
5Lipoprotein(a)IBA
12/2007 - 04/2002
4Glucose (Dextrose)FDA LinkGeneric
04/2021 - 11/2006
4AntibodiesIBA
01/2019 - 02/2012
4Serotonin (5 Hydroxytryptamine)IBA
01/2019 - 01/2010
4Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/2019 - 10/2012
4Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
05/2015 - 06/2008
4AN-1792IBA
03/2014 - 11/2010
4Neurotransmitter Agents (Neurotransmitter)IBA
01/2013 - 12/2009
4Amyloid Precursor Protein Secretases (beta-Secretase)IBA
01/2012 - 01/2009
3CoffeeFDA Link
06/2022 - 01/2015
3IronIBA
11/2021 - 11/2006
3Interleukin-6 (Interleukin 6)IBA
01/2021 - 10/2004
3MicronutrientsIBA
01/2018 - 03/2008
3gantenerumabIBA
01/2018 - 03/2014
3HomocysteineIBA
01/2018 - 02/2006
3Botulinum Toxins (Botulinum Toxin)IBA
09/2017 - 10/2010
3Vitamin B Complex (B Vitamins)IBA
05/2009 - 03/2006
2Retinaldehyde (Retinal)IBA
02/2022 - 11/2021
2Protein Isoforms (Isoforms)IBA
01/2022 - 02/2006
2Apolipoprotein E4IBA
01/2022 - 12/2011
2Apolipoprotein E2IBA
01/2022 - 09/2010
2Triiodothyronine (Liothyronine)FDA LinkGeneric
04/2021 - 10/2020

Therapy/Procedure

20Therapeutics
01/2021 - 11/2008
9Mediterranean Diet
01/2022 - 10/2006
9Immunotherapy
01/2019 - 11/2010
8Activities of Daily Living (ADL)
01/2017 - 01/2007
7Secondary Prevention
08/2022 - 01/2010
7Continuous Ambulatory Peritoneal Dialysis (CAPD)
11/2021 - 01/2019
7Injections
02/2019 - 10/2009
6Institutionalization (Institutionalized Persons)
11/2021 - 01/2007
4Extracorporeal Shockwave Therapy
01/2019 - 02/2013